Hideo Yoshida

Dr. Hideo Yoshida

Japanese Red Cross Medical Center
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KTKaoru Tsuchiya
Kaoru Tsuchiya
MKMasayuki Kurosaki
Masayuki Kurosaki
ASAzusa Sakamoto
Azusa Sakamoto
HMHiroyuki Marusawa
Hiroyuki Marusawa
YKYuji Kojima
Yuji Kojima
OGon behalf of Japanese Red Cross Liver Study Group
on behalf of Japanese Red Cross Liver Study Group
Background: Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN in real-world practice. Methods: A total of 343 u-HCC patients who received LEN from March 2018 to May 2020 at 23 sites in Japan were registered. Results: During the median observation period of 10.5 months, 143 patients died. In Child-Pugh A (n = 276) and Child-Pugh B (n = 67) patients, the median overall survival (OS) was 21.0 and 9.0 months. The median progression-free survival (PFS) was 8.8 months in Child-Pugh A patients. The objective response rate (ORR) and disease control rate (DCR) according to modified response evaluation criteria in solid tumors (RECIST criteria) were 42.1% and 82.1%. The independent pretreatment factors associated with mortality in all patients were AFP ≥ 400 ng/mL (hazard ratio (HR) 2.00, 95% confidential interval (95% CI) 1.08–2.09, p < 0.0001), modified albumin-bilirubin (ALBI) grade 2b or 3 (HR 1.56, 95% CI 1.09–2.17, p = 0.012), major vascular invasion (HR 1.91, 95% CI 1.26–2.89, p = 0.0022), PS > 0 (HR 1.50, 95% CI 1.09–2.08, p = 0.014), and MTT (molecular targeted therapy) experience (HR 2.22, 95% CI 1.56–3.13, p = 0.00038). In the MTT naïve patients with ALBI grade 1 or modified ALBI 2a and BCLC stage B (n = 68), median OS and PFS were 25.3 and 12.3 months. Liver-related adverse events during LEN were the only significant adverse event associated with OS (HR 2.74, 95% CI 1.93–3.88, p < 0.0001). Among the Child-Pugh A patients with extrahepatic metastasis and no major vascular invasion, median PFS in the patients with bone metastasis was significantly shorter than those with lung or adrenal grand metastasis (6.3 vs. 12.5 months, p = 0.0025). Conclusion: LEN showed a high response rate in real-world practice. Pretreatment factors, including ALBI score, AFP, and major vascular invasion are important in making a treatment strategy for patients with u-HCC. The patients with bone metastasis would be candidates for new therapeutic approaches.

15 September 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
TMTatsuya Minami
Tatsuya Minami
MSMasaya Sato
Masaya Sato
HTHidenori Toyoda
Hidenori Toyoda
SYSatoshi Yasuda
Satoshi Yasuda
TYTomoharu Yamada
Tomoharu Yamada
RTRyosuke Tateishi
Ryosuke Tateishi

1 September 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
HYHideo Yoshida
Hideo Yoshida
NKNaoya Kato
Naoya Kato
YSYasushi Shiratori
Yasushi Shiratori
RSRunxuan Shao
Runxuan Shao
YWYue Wang
Yue Wang
MOMasao Omata
Masao Omata
Recently, a novel DNA virus designated SEN virus (SEN-V), which is thought to be related to posttransfusion hepatitis, was discovered. The aim of the present study was to clarify the relationship between SEN-V infection and the development of liver disease. We examined SEN-V from the sera of 21 patients with non-B, non-C hepatocellular carcinoma (HCC) and 13 patients with non-B, non-C chronic liver disease (CLD) without HCC who were admitted to our hospital between 1995 and 1997. Thirty-two patients without liver disease served as controls and were also examined for SEN-V. SEN-V DNA was detected by the nested PCR method after extraction of DNA from serum. SEN-V DNA was detected in 74% (25 of 34) of patients with CLD with or without HCC who were negative for both hepatitis B virus surface antigen and anti-hepatitis C virus antibody. SEN-V DNA was detected in 69% (9 of 13) of CLD patients without HCC and in 76% (16 of 21) of HCC patients. The prevalence of SEN-V was no higher in patients with liver disease than in patients without liver disease (24 of 32; 75%). There were no significant differences in age, sex, liver function, history of blood transfusion, or amount of alcohol intake between SEN-V-positive and SEN-V-negative CLD and HCC patients. Genetic analysis suggested that SEN-V is closely related to the TT virus family. SEN-V was detected at almost the same frequency in patients with and without liver disease. SEN-V does not seem to contribute either to the pathogenesis of liver disease or to the development of HCC from chronic liver disease.

1 August 1995 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
MAMasayuki Azuma
Masayuki Azuma
TTTetsuya Tamatani
Tetsuya Tamatani
KFKazuhiro Fukui
Kazuhiro Fukui
TYTokuyuki Yuki
Tokuyuki Yuki
Mohammad Obaidul HoqueMohammad Obaidul Hoque
Mohammad Obaidul Hoque
MSMitsunobu Sato
Mitsunobu Sato

1 September 2008 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
THTomoro Hishiki
Tomoro Hishiki
TSTakeshi Saito
Takeshi Saito
KTKeita Terui
Keita Terui
TMTetsuya Mitsunaga
Tetsuya Mitsunaga
MNMitsuyuki Nakata
Mitsuyuki Nakata
HYHideo Yoshida
Hideo Yoshida

30 May 2001 in Surgery Today
Verified
Journal Article
Closed access
PDF file
TOTadao Okada
Tadao Okada
HYHideo Yoshida
Hideo Yoshida
JIJun Iwai
Jun Iwai
TMTadashi Matsunaga
Tadashi Matsunaga
YOYasuhiro Ohtsuka
Yasuhiro Ohtsuka
NONaomi Ohnuma
Naomi Ohnuma